Wall Street analyst estimates for MDxHealth S.A. (MDXH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-13 | $-0.18 | $-0.19 | +6.9% |
| 2026-05-13 | $-0.19 | $-0.13 | -46.2% |
| 2025-11-12 | $-0.16 | $-0.12 | -33.3% |
| 2025-05-14 | $-0.19 | $-0.13 | -46.2% |
| 2024-11-06 | $-0.40 | $-0.27 | -48.1% |
| 2024-05-01 | $-0.31 | $-0.30 | -3.3% |
| 2023-11-08 | $-0.40 | $-0.31 | -29.0% |
| 2023-05-15 | $-0.05 | $-0.40 | +87.5% |
Valuation Ratios
| Price / Book | -2.89 |
| EV / EBITDA | -17.51 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.9M | $40.5M | $28.3M | $11.8M | $18.5M | $22.2M | $37.1M | $70.2M | $90.0M | $107.9M |
| Cost of Revenue | $10.1M | $10.2M | $11.7M | $11.9M | $10.4M | $11.7M | $17.8M | $26.3M | $34.9M | $43.4M |
| Gross Profit | $19.8M | $30.3M | $16.7M | -$144000 | $8.0M | $10.6M | $19.2M | $43.9M | $55.1M | $64.4M |
| Research & Development | -$332000 | $1.8M | $1.8M | $9.0M | $4.5M | $5.6M | $7.6M | $6.4M | $10.6M | $10.3M |
| Selling, General & Admin | $11.6M | $13.5M | $15.3M | $10.1M | $28.6M | $30.2M | $50.1M | $59.9M | $61.4M | $66.8M |
| Operating Expenses | $32.6M | $42.6M | $48.8M | $43.0M | $35.2M | $37.4M | $57.1M | $71.3M | $79.9M | $79.8M |
| Operating Income | -$12.8M | -$12.3M | -$32.1M | -$43.2M | -$27.1M | -$26.8M | -$37.9M | -$27.3M | -$24.7M | -$15.4M |
| EBITDA | -$11.6M | -$10.2M | -$29.5M | -$39.7M | -$24.0M | -$24.1M | -$36.4M | -$30.5M | -$22.0M | -$14.0M |
| Interest Expense | 0 | $122000 | $82000 | $516000 | $1.5M | $1.9M | $2.7M | $5.8M | $7.6M | $12.2M |
| Pre-tax Income | -$13.3M | -$12.4M | -$32.5M | -$43.7M | -$28.7M | -$29.0M | -$44.0M | -$43.1M | -$37.7M | -$35.4M |
| Income Tax | -$113000 | -$113000 | -$41000 | -$575000 | 0 | 0 | 0 | $1000 | $382000 | -$1.9M |
| Net Income | -$13.2M | -$12.3M | -$32.5M | -$43.1M | -$28.7M | -$29.0M | -$44.0M | -$43.1M | -$38.1M | -$33.5M |
| EPS | $-2.86 | $-2.46 | $-5.63 | $-6.89 | $-3.44 | $-2.38 | $-2.78 | $-1.66 | $-0.78 | $-0.67 |
| EPS (Diluted) | $-2.86 | $-2.46 | $-5.63 | $-6.89 | $-3.44 | $-2.38 | $-2.78 | $-1.66 | $-1.16 | $-0.67 |
| Shares Outstanding (Diluted) | $4.6M | $5.0M | $5.8M | $6.3M | $8.3M | $12.2M | $15.9M | $25.9M | $48.7M | $50.0M |
Price
| Price | $0.65 |
| Market Cap | $33M |
| Exchange | NASDAQ |
| Country | BE |
Related companies: ACRS · ASMB · IMRX · NEO · QTRX · SI · SNWV
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MDXH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks